A research scientist at BD.AP
Beckton Dickinson on Monday announced a $24 billion deal to acquire the medical technology company Bard, and a small Wall Street firm that has closed some major deals recently is involved.
Perella Weinberg is acting as the lead financial adviser to BD on the deal, with Citi also serving as an adviser and providing fully committed financing. Goldman Sachs is serving as the lone financial adviser to Bard.
Advisory fees for Perella Weinberg and Citi could total up to $50 million, while Goldman Sachs could make up to $60 million, according to the consultant Freeman & Co.
This marks Perella Weiberg’s second major healthcare merger deal in as many weeks, having advised Cardinal Health in a $6.1 billion deal with Medtronic announced April 18.
The firm, which was founded in 2006, also advised Medtronic on its $42.9 billion takeover of Covidien in 2014 and was a part of AT&T’s $84.5 billion acquisition of Time Warner.
The healthcare sector has been one of the busiest for investment-banking activity in 2017, ranking behind only technology, financial institutions, and energy and natural resources, according to Dealogic.